Physician

Mudappa Karineravanda Kalaiah, MD

According to 2025 Medicare claims, Mudappa Kalaiah, MD (NPI: 1942457981) practices rheumatology in the Davenport-Moline-Rock Island, IA-IL market, with the plurality of this provider's patient population coming from Scott, IA. This provider's primary affiliated billing organization is RHEUMATOLOGY ASSOCIATES, PC (NPI: 1851578868; TIN: 261643846) and primary practice location at 52722-1624. Kalaiah is affiliated with the IRCCO (ACO ID: A2619), Genesis Accountable Care Organization, LLC. (ACO ID: A4799), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Kalaiah's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 377 traditional Medicare patients, billed 78,988 HCPCS/CPT codes, and received $997,934 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,758 prescription claims across 537 beneficiaries totaling $3,406,948 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 15 records totaling $274. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $878,062 to $997,934. Similarly, Part D prescription costs have moved sharply higher in recent years, from $60,945 to $3,406,948. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	274	36,210	$878,062
2016	266	33,233	$881,426
2017	383	6,874	$234,223
2018	467	11,865	$359,085
2019	439	12,794	$305,061
2020	301	20,709	$422,844
2021	274	29,484	$666,479
2022	268	36,994	$721,837
2023	362	55,216	$853,357
2024	377	78,988	$997,934

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	106	592	$60,945
2016	87	472	$55,495
2017	123	615	$48,571
2018	178	943	$109,970
2019	257	1,371	$374,182
2020	264	1,742	$661,334
2021	330	2,233	$950,410
2022	381	2,629	$1,180,929
2023	432	2,939	$1,774,983
2024	537	3,758	$3,406,948

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	285	636	$86
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	219	355	$11
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	230	422	$8
82565	Blood creatinine level	225	407	$5
85651	Red blood cell sedimentation rate, to detect inflammation, non-automated	238	469	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	125	3,836	$1,058,181
Enbrel Sureclick	Etanercept	73	2,058	$566,166
Skyrizi Pen	Risankizumab-Rzaa	14	1,064	$319,435
Enbrel Mini	Etanercept	27	756	$198,829
Rinvoq	Upadacitinib	25	750	$157,255

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	15	$274	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mudappa Karineravanda Kalaiah, MD?

Tedicare shows public-source Medicare data for Mudappa Karineravanda Kalaiah, MD (NPI 1942457981), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mudappa Karineravanda Kalaiah, MD have ACO affiliation data?

Mudappa Karineravanda Kalaiah, MD is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619), Genesis Accountable Care Organization, LLC. (MSSP, ACO ID A4799), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Mudappa Karineravanda Kalaiah, MD?

Mudappa Karineravanda Kalaiah, MD is linked to RHEUMATOLOGY ASSOCIATES, PC (billing NPI 1851578868) in the available physician profile data.

Does Mudappa Karineravanda Kalaiah, MD have Open Payments data?

Mudappa Karineravanda Kalaiah, MD has 15 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.